Intest Res.  2014 Oct;12(4):287-292. 10.5217/ir.2014.12.4.287.

Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study

  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
  • 2Mackay Junior College of Medicine, Nursing and Management, Taipei, Taiwan.
  • 3Mackay Medical College, New Taipei, Taiwan.
  • 4Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
  • 5Division of Gastroenterology and Hepatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
  • 6Division of Colon and Rectal Surgery, Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
  • 7Department of Internal Medicine, Medical College and Hospital, National Cheng-Kung University, Tainan, Taiwan.
  • 8Division of Gastroenterology, Chung Shan Medical University, Taichung, Taiwan.
  • 9Department of Gastroenterology, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • 10Department of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan.
  • 11Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
  • 12Department of Surgery, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
  • 13Division of Gastroenterology, Department of Medicine, Show Chwan Memorial Hospital, Changhuan, Taiwan.
  • 14Department of Pediatrics, National Taiwan University, Taipei, Taiwan.


Only moderate to severe Crohn's Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Japan and Korea. We aim to explore the efficacy of using adalimumab in CD patients under such stringent criteria.
A retrospective analysis was conducted in nine medical centers in Taiwan and we collected the results of CD patients receiving adalimumab from Sep 2009 to Mar 2014. The clinical characteristics, response measured by CDAI (Crohn's Disease Activity Index), adverse events and survival status were recorded and analyzed. CR-70, CR-100, and CR-150 were defined as attaining a CDAI decrease of 70, 100 or 150 points compared with baseline.
A total of 103 CD patient records were used in this study. Sixty percent of these patients received combination therapy of adalimumab together with immunomodulators. CR-70 was 68.7%, 74.5% and 88.4% after week 4, 8 and 12 of treatment, respectively. The steroid-free rate, complications and survival were 47.6%, 9.7% and 99% of patients, respectively. In considering the mucosal healing, only 25% patients achieve mucosal healing after treatment for 6 to12 months. Surgery was still needed in 16.5% of patients. Combination treatment of adalimumab with immunomodulators further decreased the level of CDAI at week 8 when compared with the monotherapy.
Even under the stringent criteria for using adalimumab, the response rate was comparable to those without stringent criteria.


Crohn disease; Adalimumab; Efficacy; Safety
Full Text Links
  • IR
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: